The University of Toledo

Vincent F. Mauro, Pharm.D., FCCP

Professor of Clinical Pharmacy
Department of Pharmacy Practice
College of Pharmacy

and

Adjunct Professor of Medicine
Department of Medicine
College of Medicine

419.383.1952
HEB 141F
vmauro@utnet.utoledo.edu

Dr. Mauro's practice and research interests include cardiovascular pharmacotherapeutics and pharmacokinetics.  He has also investigated intravenous medication incompatibilities related to cardiovascular medications.

Dr. Mauro lectures in numerous courses throughout both the undergraduate and post-baccalaureate curriculums.  He has been recongized by his students as an outstanding teacher on multiple occassions.

Dr. Mauro is a member of the American College of Clinical Pharmacy, the American Society of Health-System Pharmacists, the American Association of Colleges of Pharmacy, the Ohio College of Clinical Pharmacy, the Ohio Society of Health-System Pharmacists, the Ohio Pharmacists Association, and the Toledo Area Society of Health-System Pharmacists. He is a member of Phi Lambda Sigma, Rho Chi, Omicron Delta Kappa, and Phi Kappa Phi honorary societies.

Publications:

Refereed Journals - Original Research

1. Mauro LS, Mauro VF, Brown DL, Somani P. Enhancement of phenytoin elimination by multiple dose activated charcoal. Ann Emerg Med. 1987;16:1132-5.
2. Kline SS, Mauro VF, Forney RB, Freimer EH, Somani P. Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia. Antimicrob Agents Chemother. 1987;31:1328-31.
3. Mauro VF, Mauro LS, Hageman JH. Alteration of pentoxifylline pharmacokinetics by cimetidine. J Clin Pharmacol. 1988;28:649-56.
4. Mauro LS, Mauro VF, Bachmann KA, Higgins JT. Accuracy of two equations at determining normalized phenytoin concentrations. DICP. 1989;23:64-8.
5. Mauro LS, Mauro VF, Miller PC, Lacher DA. Effect of cefotetan on creatinine determination by the picric acid and enzymatic methods. Clin Pharm. 1989;8:505-8.
6. Lee CY, Mauro VF, Alexander KS. Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs. Am J Hosp Pharm. 1990; 47:606-8.
7. Mauro VF, Mauro LS, Fraker TD, Temesy-Armos PN, Somani P. Effect of aluminum hydroxide gel on quinidine gluconate absorption. DICP Ann Pharmacother. 1990; 24:252-4.
8. Mauro LS, Mauro VF. Effect of serum separator tubes on serum quinidine concentration measurements. Clin Pharm. 1990; 9: 292-4.
9. Mauro LS, Mauro VF. Effect of serum separator tubes on free and total phenytoin and carbamazepine serum concentrations. Ther Drug Monitor. 1991; 13:240-3.
10. Mauro VF, Mauro LS, Hageman JH. Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. J Clin Pharmacol. 1992; 32:1054-8.
11. Knapp AJ, Mauro VF, Alexander KS. Incompatibility of ketorolac with other injectable medications. Am J Hosp Pharm. 1992; 49:2960-2.
12. Mauro VF, Mauro LS, Klions HH. Effect of single dose fluoxetine on theophylline serum concentrations. Am J Ther. 1994; 1:304-8.
13. Mauro VF, Jacobs LR, Mauro LS, MacArthur RD, White DB. Comparison of tobramycin pharmacokinetics after administration by CRIS and a traditional intravenous piggyback infusion. Ann Pharmacother. 1995; 29:465-9.
14. Mauro LS, Kuhl DA, Kirchhoff JR, Mauro VF, Hamilton RW. Impact of oral bases on aluminum absorption. Am J Ther. 2001; 8:21-5.
15. Mauro VF, Mauro LS, Kleshinski JF, Erhardt PW. Impact of Ginkgo Biloba on digoxin. Am J Ther. 2003; 10:247-51.
16. Honisko ME, Fink JM, Militello MA, Mauro VF, Alexander KS. Compatibility of argatroban with selected cardiovascular agents. Am J Health-Syst Pharm. 2004; 61:2415-8.
17. Newland AM, Mauro VF, Alexander KS.  Physical compatibility of metroprolol tartrate injection with selected cardiovascular agents (letter).  Am J Health-Syst Pharm. 2009; 66:986-7. 

1. Mauro VF, Zeller FP. Early use of beta-adrenergic-blocking agents in acute myocardial infarction. Drug Intell Clin Pharm. 1986; 20:14-9.
2. Mauro VF, Mauro LS. Use of intermittent dobutamine infusion in congestive heart failure. Drug Intell Clin Pharm. 1986;20:919-24.
3. Buenger JW, Mauro VF. Organic nitrate-induced methemoglobinemia. DICP. 1989;23:283-8.
4. Mauro VF, Mauro LS. Pathophysiology and pharmacotherapy of angina pectoris. Clin Trends Hosp Pharm. 1990; 4:45-56.
5. Mauro VF, MacDonald JL. Simvastatin: a review of its pharmacology and clinical use. DICP Ann Pharmacother. 1991; 25:257-64.
6. Stoneman DK, Mauro VF. The role of heparin in the thrombolytic treatment of acute myocardial infarction. J Pharm Technol. 1992; 8:105-10.
7. Mauro VF, Frazee LA. Use of fish oil to prevent coronary angioplasty restenosis. Ann Pharmacother. 1992; 26:1541-5.
8. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokin. 1993; 24:195-202.
9. Mauro VF, Mauro LS. Pathophysiology and pharmacotherapy of Parkinson’s disease - Part I. Clin Trends Hosp Pharm. 1993; 7:1-4.
10. Mauro VF, Mauro LS. Pathophysiology and pharmacotherapy of Parkinson’s disease - Part II. Clin Trends Hosp Pharm. 1993; 7:13-20.
11. Mauro VF. An introduction to clinical laboratory tests. Am J Pharm Educ. 1993; 57:148-52.
12. Hailemeskel B, Mauro VF. The use of angiotensin converting enzyme inhibitors in heart failure. J Pharm Technol. 1994; 10:156-63.
13. Mauro LS, Nawarskas JJ, Mauro VF. Misadventures with activated charcoal and recommendations for safe use. Ann Pharmacother. 1994; 28:915-24.
14. Genetta TB, Mauro VF. Abciximab: a new antiaggregant used in angioplasty. Ann Pharmacother. 1996; 30:251-7.
15. Lazarus JC, Mauro VF. Syncope: pathophysiology, diagnosis, and pharmacotherapy. Ann Pharmacother. 1996; 30:994-1005.
16. Mauro VF. Focus on midodrine: an oral peripheral-acting alpha-agonist for the treatment of orthostatic hypotension. Formulary 1997; 32:225-31.
17. Bizjak ED, Mauro VF. Thrombolytic therapy: a review of its use in acute myocardial infarction. Ann Pharmacother. 1998; 32:769-84.
18. Kalus JS, Mauro VF. Dofetilide: a class III-specific antiarrhythmic agent. Ann Pharmacother. 2000; 34:44-56.
19. Spinler SA, Hilleman D, Cheng JWM, Howard P, Mauro VF, Lopez L, et al. New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines. Ann Pharmacother. 2001;35:589-617.
20. Sciulli TM, Mauro VF. Pharmacology and clinical use of bivalirudin. Ann Pharmacother. 2002;36:1028-41.
21. Mauro VF, Tuckerman CE. Ezetimibe for management of hypercholesterolemia. Ann Pharmacother. 2003; 37:839-848.
22. Anthony KK, Mauro VF. Rate versus rhythm control in atrial fibrillation. Ann Pharmacother. 2004; 38:839-44.
23. Sweeney MA, Mauro VF,Cable JL, Rudnicki BM, Wall AL, Murphy CC, et al. Community pharmacists and colleges of pharmacy: the Ohio partnership. J Am Pharm Assoc. 2005; 45:82-7.

1. Mauro VF, Bonfiglio MF, Spunt AL. Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia. Clin Pharm. 1986;5:837-9.
2. Bonfiglio MF, Mauro VF. Naloxone in the treatment of meperidine-induced seizures. Drug Intell Clin Pharm. 1987;21:174-5.
3. Mauro VF, Somani P, Temesy-Armos PN. Drug interaction between lorcainide and rifampicin. Eur J Clin Pharmacol. 1987;31:737-8.
4. Mauro VF, Bingle JF, Ginn SM, Jafri FM. Torsade de pointes in a patient receiving vasopressin. Crit Care Med. 1988;16:200-1.
5. Keith RL, Mauro LS, Mauro VF. Beta-blocker alternatives in essential tremor. Drug Intell Clin Pharm. 1988;22:613-4.
6. Mauro LS, Mauro VF, Bachmann KA. Phenytoin equation accuracy - Reply (Letter). DICP. 1989;23:621-2.
7. Haug MT, Mauro VF, Davis HH. Effect of renal failure and hemodialysis on aminocaproic acid plasma concentrations (Letter). DICP. 1989; 23:922-3.
8. Mauro VF, Mauro LS, Kepler L. Digoxin-diltiazem drug interaction. DrugDex: Drug Consults. Vol 70:1991.
9. Mauro VF. Cyberlog: A library of applied medical software: Arrhythmia. (Book Review) DICP Ann Pharmacother. 1991; 25:684.
10. Mauro VF, Mauro LS. Applied Therapeutics, 5th ed. (Book Review) Clin Pharm. 1992; 11:897-900.
11. Hagmeyer KO, Mauro LS, Mauro VF. Meperidine use-related seizures associated with patient controlled analgesia pumps. Ann Pharmacother. 1993; 27:29-32.
12. Chesser SL, Mauro VF. Antistreptokinase antibodies following a dose of streptokinase. Ann Pharmacother. 1994; 28:204-6.
13. Daniel JR, Mauro VF. Extrapyramidal symptoms associated with calcium-channel blockers. Ann Pharmacother. 1995; 29:73-5.
14. Biery JC, Mauro VF. Adenosine in acute theophylline intoxication. Ann Pharmacother. 1995; 29:1285-7.
15. Southworth MR, Mauro VF. The use of HMG CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients. Ann Pharmacother. 1997; 31:489-91.
16. Kauflin MJ, Mauro VF. The use of organic nitrates in the acute and chronic phases of myocardial infarction: impact on survival. DrugDex: Drug Consults. Vol. 91:1997.
17. Bizjak ED, Mauro VF. Digoxin-macrolide drug interaction. Ann Pharmacother. 1997; 31:1077-9.
18. Rose LM, Ohlinger MJ, Mauro VF. A hypertensive reaction induced by concurrent use of selegiline and dopamine. Ann Pharmacother. 2000; 34:1020-4.
19. Lloyd SJ, Mauro VF. Spironolactone in the treatment of congestive heart failure. Ann Pharmacother. 2000;34:1336-40.
20. Kerst LL, Mauro VF. Coronary event secondary prevention with statins irrespective of LDL-Cholesterol. Ann Pharmacother. 2004; 38:1060-4.
21. Earl MA, Mauro VF. The clinical impact of administering warfarin to post-MI patients. J Pharm Pract. 204; 17:266-9.

1. Mauro VF. Listing of antihypertensive medications. In: Ganten D, Mulrow PJ, eds. Handbook of experimental pharmacology, Vol. 93. Pharmacology of antihypertensive therapeutics. Heidelberg: Springer-Verlag, 1990: 861-99.

1. Militello MA, Mauro VF, eds. Drug information handbook for cardiology: 2006. Hudson, OH: Lexi-Comp, 2006.

1. Mauro VF. Hospital pharmacy simulations in cardiovascular medicine: Angina. Norwalk, CT: Medical Age Publishing, 1994.
2. Mauro VF. Congestive heart failure: Pathophysiology and clinical presentation. Hackensack, NJ: Innovative Communications, 1998.
3. Mauro VF. Congestive heart failure: Pharmacotherapy. Hackensack, NJ: Innovative Communications, 1998.
4. Mauro VF. Congestive heart failure: Treatment of concurrent hypertension and ischemia. Hackensack, NJ: Innovative Communications, 1999.

1. Schmude KA, Mauro VF. Pearls to prevent pharmacy perils: Azathioprine-allopurinol drug interaction. Ohio Pharmacist. 2001;50 (January):15.
2. Schmude KA, Mauro VF. Pearls to prevent pharmacy perils: Discontinuation of carbamazepine. Ohio Pharmacist. 2001;50 (March):21.
3. Ahrens CL, Mauro VF. Pearls to prevent pharmacy perils: MAO-I-dextromethorphan drug interaction. Ohio Pharmacist. 2001;50 (April):19-20.
4. Wuo GS, Mauro VF. Pearls to prevent pharmacy perils: Lithium-diuretic drug interaction. Ohio Pharmacist. 2001;50 (June):20-21.
5. Mauro VF. Pearls to prevent pharmacy perils: Amantadine dosing. Ohio Pharmacist. 2001;50 (September):20-21.
6. Glowczewski JE, Mauro VF. Pearls to prevent pharmacy perils: Treating hypoglycemia in a patient on acarbose. Ohio Pharmacist. 2001:50 (December):14-15.
7. Sciulli TM, Mauro VF. Pearls to prevent pharmacy perils: Dofetilide. Ohio Pharmacist. 2002;51 (May):20-21.
8. Rigelsky FS, Mauro VF. Pearls to prevent pharmacy perils: St. John’s wort. Ohio Pharmacist. 2002;51 (October):17.
9. Schlak JH, Mauro VF. Pearls to prevent pharmacy perils: Thyroid-warfarin drug interaction. Ohio Pharmacist. 2003;52 (January):19-20.
10. Morgan ME, Mauro VF. Pearls to prevent pharmacy perils: Nefazodone-cyclosporine drug interaction. Ohio Pharmacist. 2003;52 (March):16-17.
11. Kramer RL, Mauro VF. Pearls to prevent pharmacy perils: Allopurinol rash. Ohio Pharmacist. 2003:52 (May):18-19.
12. Abbott GV, Mauro VF, Mauro LS. Pearls to prevent pharmacy perils: Use of magnesium in renal failure. Ohio Pharmacist. 2003;52 (July):18-19.
13. Popa D, Mauro VF. Pearls to prevent pharmacy perils: Itraconazole-proton pump inhibitor drug interaction. Ohio Pharmacist. 2003;52 (October):18-19.
14. Ohwofahworaye E, Mauro VF. Pearls to prevent pharmacy perils: Ergotamine-erythromycin drug interaction. Ohio Pharmacist. 2004;53 (July):18-19.
15. Marsteller JE, Mauro VF, Burket MW. Pearls to prevent pharmacy perils: Clopidogrel therapy in stent patients. Ohio Pharmacist. 2005;54 (January):20-21,18.
16. Kaun MA, Mauro VF. Pearls to prevent pharmacy perils: Linezolid use with SSRI’s. Ohio Pharmacist. 2005;54 (May):18-19.
17. Snyder LM, Mauro VF. Pearls to prevent pharmacy perils: Salt substitutes warning. Ohio Pharmacist. 2005;54 (December):20-21.
18. Blanco KA, Mauro VF. Pearls to prevent pharmacy perils: Colchicine drug interactions. Ohio Pharmacist. 2006;55 (March):20-21.
19. Owens JA, Mauro VF. Pearls to prevent pharmacy perils: New clopidogrel recommendations with drug-eluting stents.  Ohio Pharmacist. 2007;56 (May):14-15.
20. Barnett JM, Mauro VF. Pearls to prevent pharmacy perils: Drug-induced peripheral swelling. Ohio Pharmacist. 2009;58 (November):14-15. 

1. Schmude KA, Mauro VF. Pharmacy pearls: Drug interaction case study – allopurinol. OSHP Bulletin 2001;21 (Jan/Feb):4-5.
2. Ahrens CL, Mauro VF. Pharmacy pearls: Drug interaction case study – meperidine. OSHP Bulletin 2001:21 (Sept/Oct):4-5.
3. Meister KE, Mauro VF. Pharmacy pearls: ARBs, ACE-Is, and beta blockers in heart failure. OSHP Bulletin. 2004;24 (Jan/Feb):4-5,7.
4. El Terk RM, Mauro VF. Pearls to prevent pharmacy perils: Timolol eye drops. OSHP Bulletin. 2006;26 (Jul/Aug):4-5.

5. Tabb NC, Mauro VF, Salamon J.  Pharmacy pearls: Nalbuphine.  OSHP Bulletin.  2008;28 (May/Jun);4-5

6. Soric MM, Mauro VF.  Pearls to prevent pharmacy perols:  Cilostazol.  OSHP Bulletin.  2009; 29 (Jan/Feb);4-5.

Posters

1. Marcus T. Haug III, Vincent F. Mauro, and Hayes Davis. Effect of Renal Failure and Hemodialysis on Aminocaproic Acid Plasma Concentrations. 1984 ASHP Midyear Clinical Meeting, Dallas, Texas.
2. Linda D. Smith, Daniel L. Brown, Vincent F. Mauro, James R. Friend, and Timothy J. Sullivan. Comparative Evaluation of Aminoglycoside Serum-Level Analysis Charts. 1986 ASHP Midyear Clinical Meeting, Las Vegas, Nevada.
3. Vincent F. Mauro, Laurie S. Mauro, John H. Hageman. Alteration of Pentoxifylline Pharmacokinetics by Cimetidine. 1987 OCCPCP Annual Meeting, Toledo, Ohio.
4. Laurie S. Mauro, Vincent F. Mauro, Daniel L. Brown, Pitambar Somani. Enhancement of Phenytoin Elimination with Multiple Dose Activated Charcoal. 1987 OCCPCP Annual Meeting, Toledo, Ohio.
5. Laurie S. Mauro, Phillip C. Miller, David A. Lacher, Vincent F. Mauro, Charles I. Hicks. Effect of Cefotetan on Serum and Urine Creatinine Determination. 1988 ACCP Meeting, Philadelphia, Pennsylvania.
6. Vincent F. Mauro, Laurie S. Mauro, Theodore D. Fraker, Peter N. Temesy-Armos, Pitambar Somani. Effect of Aluminum Hydroxide on Quinidine Gluconate Absorption. 1989 OCCPCP Annual Meeting, Columbus, Ohio.
7. Laurie S. Mauro, Vincent F. Mauro. Effect of Serum Separator Tubes on Serum Quinidine Concentrations. 1989 OCCPCP Annual Meeting, Columbus, Ohio.
8. Mauro LS, Mauro VF. Effect of Serum Separator Tubes on Free and Total Serum Phenytoin Concentration Measurements. 1990 OCCPCP Annual Meeting, Dellroy, Ohio.
9. Mauro LS, Mauro VF. Effect of Serum Separator Tubes on Free and Total Phenytoin and Carbamazepine Concentration Measurements. 1991 ACCP Winter Practice and Research Forum, Fort Lauderdale, Florida.
10. Mauro VF, Mauro LS, Hageman JH. Effect of Smoking on Pentoxifylline Pharmacokinetics. 1991 OCCPCP Annual Meeting, Toledo, Ohio.
11. Neiger KM, Mauro VF, Kline SS. Evaluation of Beta-Blocker Use at an Acute Care Teaching Hospital. 1992 ASHP Midyear Clinical Meeting, Orlando, Florida.
12. Mauro VF, Mauro LS, Klions, HH. Effect of Single Dose Fluoxetine on Aminophylline Pharmacokinetics. 1994 ACCP Meeting, St. Louis, Missouri.
13. Mauro LS, Kuhl DA, Kirchhoff JR, Mauro VF, Hamilton RW. Effect of Oral Bases on Aluminum Absorption. 1995 ACCP Winter Practice and Research Forum, Orlando, Florida.
14. Ahrens CL, Mauro LS, Mauro VF. Evaluation of a Weight-based Heparin Dosing Protocol in Obesity. 2000 ASHP Midyear Clinical Meeting, Las Vegas, Nevada.
15. Sciulli TM, Mauro VF. Assessing the Economic Incentive for Split-tablet Dosing. 2001 OPA Annual Conference, Columbus, Ohio.
16. Mauro VF, Mauro LS, Kleshinski J, Erhardt P. Impact of Ginkgo Biloba on the Pharmacokinetics of Digoxin. 2001 ACCP Spring Practice and Research Forum, Salt Lake City, Utah.
17. Abramcyzyk TM, Mauro VF.  Impact of restarting warfarin in hospitalized patients following use of phytonadione.  2008 ASHP Midyear Clinical Meeting, Orlando, FL.
18. Zukkoor SM, Mauro VF, Churchwell M. Atorvastatin 80 mg daily therapy for acute coronary syndrome: an assessment of short and long term tolerability. 2009 ASHP Midyear Clinical Meeting, Las Vegas, Nevada.
19. Taylor LA, Mauro VF. Incidence of bleeding in renally-impaired percutaneous coronary intervention patients receiving incorrectly-dosed eptifibatide or bivalirudin. 2010 ASHP Midyear Clinical Meeting, Anaheim, California. 

1. Mauro VF*, Mauro LS, Klions HH. Effect of Single Dose Fluoxetine on Theophylline Serum Concentrations. 1995 OhCCP Annual Meeting-Fall Session, Painesville, OH.
2. Gundrum TD*, Mauro VF. Drug-Induced Bradycardia. 1996 OhCCP Annual Meeting-Fall Session, Beachwood, OH.
3. Mauro VF*, Mauro LS, Kleshinski J, Erhardt P. The Effect of Ginkgo Biloba on Digoxin Pharmacokinetics. 2000 OhCCP Annual Meeting-Fall Session, Beachwood, OH.
4. Ahrens CL*, Mauro LS, Mauro VF. Evaluation of a Weight-based Heparin Dosing Protocol in Obese Patients. 2000 OhCCP Annual Meeting-Fall Session, Beachwood, OH.
5. Abramcyzyk TM*, Mauro VF.  Impact of restarting warfarin in hospitalized patients following use of phytonadione.  2009 Great Lakes Residency Conference, Purdue University, West Lafayette, IN.  (Preliminary work was presented as a poster at 2008 ASHP Mid-year Clinical Meeting.) 
6. Zukkoor SM*, Mauro VF, Churchwell M. Atorvastatin 80 mg daily therapy for acute coronary syndrome: an assessment of short and long term tolerability. 2010 Great Lakes Residency Conference, Purdue University, West Lafayette, IN. (Preliminary work was presented as a poster at 2009 ASHP Mid-year Clinical Meeting.)
7. Taylor LA*, Mauro VF. Incidence of bleeding in renally-impaired percutaneous coronary intervention patients receiving incorrectly-dosed eptifibatide or bivalirudin.  2011 Great Lakes Residency Conference, Purdue University, West Lafayette, IN. (Preliminary work was presented as a poster at 2010 ASHP Mid-year Clinical Meeting.)